US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

Diamyd informs in quarterly report of the objective to file for market approval for the Diamyd® diabetes vaccine in 2011

In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.During the first quarter Diamyd Medical has reported several important events that have contributed positively to the Company’s development. The financial position has been strengthened through an oversubscribed preferential rights issue, which brought in just over MSEK 219 before issue expenses. The European Phase III study with Diamyd® has been fully

Diamyd makes investment in time-to-market

Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd®.Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd®, including in total 640 children and adolescents with recent-onset type 1 diabetes. The program is composed of one study in the US and one parallel study in nine countries in Europe. The US recruitment effort will soon be launched together with

Diamyd to include children and accelerate patient recruitment in US Phase III study with the Diamyd® diabetes vaccine

Diamyd Medical reported today that from September 1, children from 10 years of age with type 1 diabetes will be included in the company’s US Phase III study of the Diamyd® diabetes vaccine. The company is also trebling the number of clinics and is investing in expanded recruitment activities in the US.Diamyd Medical’s Phase III study of the Diamyd® diabetes vaccine in the US has so far only been open to patients with type 1 diabetes aged between 16 and 20 years. From September 1, 2009, the study will also be open to children in the age range 10 to 15 years. Following the FDA’s decision in

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media